ClinicalTrials.gg
CompletedNCT05174416Updated Sep 19, 2024Results posted

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

A Phase 3 interventional study of Mavacamten and Placebo in Obstructive Hypertrophic Cardiomyopathy, sponsored by LianBio LLC. Completed at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by LianBio LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
9th of 21
81 · median 75
Started
2022
with 3 others
Phase 3
6 of 21
none open now
Registered
10th of 21
by date
Lead sponsor
2 of 21
LianBio LLC

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is one of 6 in phase 3, and was the 10th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.

Read the detailed description

This is a randomized, double-blinded, placebo-controlled clinical study witha long-term extension to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM. Approximately 81eligible participants will be enrolled and randomized in a 2:1 ratio (mavacamten:placebo). Participants will receive mavacamten or matching placebofor 30 weeks indouble-blinded manner. After 30-week double-blinded placebo-controlled treatment, eligible participants will receive mavacamten for additional 48 weeks (placebogroup: switch from placebo to mavacamten, mavacamten group: maintain on mavacamten).

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy

Keywords

  • Mavacamten
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years old at screening.
  • Body weight is greater than 45 kg at screening.
  • Has adequate acoustic windows to enable accurate TTEs
  • Diagnosed with oHCM
  • Has documented ≥ 55% at rest.
  • Has a valid measurement of Valsalva LVOT peak gradient at screening
  • Has Class II or III symptoms at screening
  • Female participants must not be pregnant or lactating
  • Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written according to national, local, and institutional guidelines before the first study specific procedure.

Exclusion criteria

Exclusion Criteria:

  • Participated in a clinical trial in which the participant received any drug (or is currently using an investigational device) within 30 days prior to screening, or at least 5 times the respective elimination half-life (if known), whichever is longer.
  • Causing cardiac hypertrophy in other reasons
  • Previously participated in a clinical study with mavacamten.
  • to any of the components of the mavacamten formulation.
  • Current treatment (within 14 days prior to screening) or planned treatment during the double-blinded treatment with a combination of beta-blockers and verapamil or a combination of beta-blockers and diltiazem.
  • Has been successfully treated with invasive septal reduction
  • Has documented obstructive coronary artery disease
  • Has known moderate or severe (as per investigator's judgment) aortic valve stenosis, constrictive pericarditis, or congenital heart disease at screening.
  • Has any acute or serious comorbid condition that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.
  • History of malignant disease within 10 years of screening
  • Has safety laboratory parameters outside normal limits at screening as assessed by the local laboratory
  • Has a positive serologic test at screening for infection with , virus, or virus surface antigen.
  • Known uncured COVID-19 (coronavirus disease 2019) infection or with severe complication before screening.
  • Has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  • Prior treatment with cardio toxic agents.
  • Unable to comply with the study requirements, including the number of required visits to the clinical site.
  • Is a first degree relative of personnel directly affiliated with the study at the clinical study site, any study vendor, or the study sponsor.
  • Identified as alcohol addicts.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Mavacamten

    Mavacamten Capsules

    Drug: Mavacamten

  • Placebo comparator
    placebo

    Matching Placebo Capsules

    Drug: Placebo

Interventions

  • Mavacamten Capsules

    Also known as: MYK-461, BMS-986327

  • DrugPlacebo

    Matching PBO capsules during placebo controlled period,and mavacamten capsules during long term extension period

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient

    To compare the effect of a 30-week course of mavacamten with placebo on Valsalva LVOT peak gradient as determined by Doppler echocardiography

    Time frame: 30 weeks

Secondary outcomes

  1. Change From Baseline to Week 30 in Resting LVOT Peak Gradient

    To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.

    Time frame: 30 weeks

  2. Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30

    To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.

    Time frame: 30 weeks

  3. Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30.

    To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.

    Time frame: 30 weeks

  4. Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30

    To compare the effect of a 30-week course of mavacamten with placebo on clinical symptoms

    Time frame: 30 weeks

  5. Change From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

    To compare the effect of a 30-week course of Mavacamten with placebo on Participant-Reported health status individually The KCCQ (23-item version) is a patient-reported questionnaire that measures the impact of patients' CV disease or its treatment on 6 distinct domains using a 2-week recall: symptoms/signs, physical limitations, quality of life, social limitations, self-efficacy, and symptom stability (Green et al., 2000). In addition to the individual domains, 2 summary scores can be calculated from the KCCQ: the overall summary score (includes the total symptom, physical limitation, social limitations and quality of life scores) and the clinical summary score (combines the total symptom and physical limitation scales). Scores range from 0 to 100, with higher scores reflecting better health status. The KCCQ will be administered to participants as indicated.

    Time frame: 30 weeks

  6. Change From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)

    To compare the effect of a 30-week course of mavacamten on cardiac biomarkers

    Time frame: 30 weeks

  7. Change From Baseline to Week 30 in Cardiac Troponin

    To compare the effect of a 30-week course of mavacamten on cardiac biomarkers

    Time frame: 30 weeks

  8. Change From Baseline to Week 30 in Left Ventricular (LV) Mass Index

    To compare the effect of a 30-week course of mavacamten with placebo on LV mass evaluated by cardiac magnetic resonance (CMR) imaging.

    Time frame: 30 weeks

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneMavacamtenPlacebo
Started5427
Completed5427
Not completed00

Outcome measures

PrimaryChange From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient

To compare the effect of a 30-week course of mavacamten with placebo on Valsalva LVOT peak gradient as determined by Doppler echocardiography

Time frame:
30 weeks
Reported as:
Mean · mmHg
Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient
mmHgMavacamtenPlacebo
Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient-51.05 ± 6.15019.23 ± 8.535
SecondaryChange From Baseline to Week 30 in Resting LVOT Peak Gradient

To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.

Time frame:
30 weeks
Reported as:
Mean · mmHg
Change From Baseline to Week 30 in Resting LVOT Peak Gradient
mmHgMavacamtenPlacebo
Change From Baseline to Week 30 in Resting LVOT Peak Gradient-49.04 ± 4.6375.95 ± 6.311
SecondaryProportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30

To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.

Time frame:
30 weeks
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30
ParticipantsMavacamtenPlacebo
Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30261
SecondaryProportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30.

To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.

Time frame:
30 weeks
Reported as:
Count of participants · Participants
Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30.
ParticipantsMavacamtenPlacebo
Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30.322
SecondaryProportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30

To compare the effect of a 30-week course of mavacamten with placebo on clinical symptoms

Time frame:
30 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30
ParticipantsMavacamtenPlacebo
Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30324
SecondaryChange From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

To compare the effect of a 30-week course of Mavacamten with placebo on Participant-Reported health status individually The KCCQ (23-item version) is a patient-reported questionnaire that measures the impact of patients' CV disease or its treatment on 6 distinct domains using a 2-week recall: symptoms/signs, physical limitations, quality of life, social limitations, self-efficacy, and symptom stability (Green et al., 2000). In addition to the individual domains, 2 summary scores can be calculated from the KCCQ: the overall summary score (includes the total symptom, physical limitation, social limitations and quality of life scores) and the clinical summary score (combines the total symptom and physical limitation scales). Scores range from 0 to 100, with higher scores reflecting better health status. The KCCQ will be administered to participants as indicated.

Time frame:
30 weeks
Reported as:
Mean · score on a scale
Change From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
score on a scaleMavacamtenPlacebo
Change From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)4.99 ± 2.063-5.25 ± 2.750
SecondaryChange From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)

To compare the effect of a 30-week course of mavacamten on cardiac biomarkers

Time frame:
30 weeks
Reported as:
Mean · ng/L
Change From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)
ng/LMavacamtenPlacebo
Change From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)0.182 ± 0.17430.932 ± 0.5133
SecondaryChange From Baseline to Week 30 in Cardiac Troponin

To compare the effect of a 30-week course of mavacamten on cardiac biomarkers

Time frame:
30 weeks
Reported as:
Mean · ng/L
Change From Baseline to Week 30 in Cardiac Troponin
ng/LMavacamtenPlacebo
Change From Baseline to Week 30 in Cardiac Troponin0.419 ± 0.19831.236 ± 0.6528
SecondaryChange From Baseline to Week 30 in Left Ventricular (LV) Mass Index

To compare the effect of a 30-week course of mavacamten with placebo on LV mass evaluated by cardiac magnetic resonance (CMR) imaging.

Time frame:
30 weeks
Reported as:
Median · g/m^2
Change From Baseline to Week 30 in Left Ventricular (LV) Mass Index
g/m^2MavacamtenPlacebo
Change From Baseline to Week 30 in Left Ventricular (LV) Mass Index-26.365 ± 21.05654.434 ± 14.4226

Adverse events

Collected over Adverse events were assessed from the first dose date of study medication up to 30 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/27 (0%)0/27 (0%)24/27 (88.9%)
Mavacamten0/54 (0%)4/54 (7.4%)45/54 (83.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboMavacamten
HaemorrhoidsGastrointestinal disorders0/271/54
Atrial flutterCardiac disorders0/271/54
fibrillationCardiac disorders0/271/54
HypotensionVascular disorders0/271/54
Ankle fractureInjury, poisoning and procedural complications0/271/54
Sinus arrestCardiac disorders0/271/54
Atrial fibrillationCardiac disorders0/271/54
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboMavacamten
COVID-19Infections and infestations11/2720/54
Upper respiratory tract infectionInfections and infestations4/278/54
HyperuricemiaMetabolism and nutrition disorders2/277/54
DizzinessNervous system disorders2/277/54
Ventricular extrasystolesCardiac disorders3/272/54
Defect conduction intraventricularCardiac disorders0/275/54
PalpitationsCardiac disorders2/273/54
Ventricular tachycardiaCardiac disorders2/272/54
HyperlipidaemiaMetabolism and nutrition disorders0/274/54
HeadacheNervous system disorders2/271/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MavacamtenPlaceboTotal
<=18 years000
Between 18 and 65 years472370
>=65 years7411
Age, Continuous
Age, Continuous(years)MavacamtenPlaceboTotal
Mean52.4 ± 12.0851.0 ± 11.8351.9 ± 11.94
Sex: Female, Male
Sex: Female, Male(Participants)MavacamtenPlaceboTotal
Female131023
Male411758
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MavacamtenPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino542781
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)MavacamtenPlaceboTotal
China542781
Valsalva LVOT peak gradient
Valsalva LVOT peak gradient(mmHg)MavacamtenPlaceboTotal
Mean106.78 ± 43.22599.79 ± 41.100104.45 ± 42.401
08

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Mar 2023, 14 months.

Results were first posted in Sep 2024, 1 year 6 months after primary completion.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Dec 30, 2021
StartActual
Jan 4, 2022
Primary completionActual
Mar 6, 2023
CompletionActual
Jul 22, 2024
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05174416
Lead sponsor
LianBio LLC
Responsible party
Sponsor
First posted
Dec 30, 2021
Start date
Jan 4, 2022
Primary completion
Mar 6, 2023
Completion
Jul 22, 2024
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Shuyang Zhang, M.D., Ph.D.
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion